Syngenta’s US$9.26 billion IPO seen as ‘huge feather in the cap’ to lure foreigners to China’s market, analysts say
- The 65 billion yuan (US$9.26 billion) offering is expected to boost foreign fund interest in China’s onshore equities market
- The listing will be a ‘huge feather in the cap’ of Chinese equity markets and exchanges, says an analyst

Shifting Syngenta’s IPO to the main board “makes sense as it provides access to a more mature market and larger liquidity base,” said Ben Harburg, managing partner at Magic Stone Alternative Investment in Beijing. The listing of the Swiss firm matches China’s drive to attract capital through regulatory improvements and investment vehicles such as qualified foreign investors, he added.
Traditionally, IPOs on Chinese exchanges have been mostly focused on domestic investors, which has limited the potential investment pool. Sinochem Holdings, a Chinese state-owned company and Syngenta’s owner, had discussed a potential reduction in the fundraising size with Chinese authorities to mollify concerns that a large offering could put pressure on liquidity in the market, Bloomberg reported last month.

“The case is intriguing and all eyes are on the SHEX’s approval process and the success of the IPO,” said Jason Hsu, chief investment officer at Rayliant Global Advisors. “SHEX and Beijing want to see a success story here. Beijing wants more global firms to list on Chinese stock exchanges. This will further legitimise China as a viable money centre.”